Prosecution Insights
Last updated: October 02, 2026

Examiner: GURLEY, JAMI MICHELLE

Tech Center 1600 • Art Units: 1647 1675

This examiner grants 53% of resolved cases

Analysis

Jami Michelle Gurley serves in Tech Center 1600 and Art Unit 1647. The profile includes 30 resolved cases, which show an allowance rate of 53.3 percent. This 53.3 percent rate provides a baseline for practitioners to estimate the probability of a grant. With 30 resolved cases, the data provides an initial look at the examiner's tendencies in this biotechnology and organic chemistry center.

The data shows an interview lift of 16.1 percent. This figure indicates that conducting an interview is associated with an increased probability of allowance compared to the baseline of cases where no interview occurs. Practitioners may consider the 16.1 percent lift when deciding whether to engage in direct communication. This positive lift suggests that verbal advocacy can be a factor in the prosecution process for Art Unit 1647.

The median days to allowance for Gurley is 1302. This 1302-day timeline provides a benchmark for the expected duration of the prosecution process from filing to grant. The combination of the 53.3 percent allowance rate and the 16.1 percent interview lift offers a roadmap for applicants. Understanding these metrics, including the 1302-day median, helps in setting expectations for both timing and results in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

53.3%
Allow Rate
-6.7% vs TC avg
54
Total Applications
+16.1%
Interview Lift
1302
Avg Prosecution Days
Based on 30 resolved cases, 2023–2026

Rejection Statute Breakdown

4.8%
§101 Eligibility
14.7%
§102 Novelty
37.7%
§103 Obviousness
26.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18438286 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER Non-Final OA Johns Hopkins University
17794917 LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF Non-Final OA Purdue Research Foundation
18571576 RECOMBINANT PROTEINS Non-Final OA FONTERRA CO-OPERATIVE GROUP LIMITED
18684660 Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof Non-Final OA ABL BIO, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month